Pictet Asset Management Holding SA Sells 32,635 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Pictet Asset Management Holding SA lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 6.8% in the first quarter, HoldingsChannel reports. The fund owned 450,764 shares of the specialty pharmaceutical company’s stock after selling 32,635 shares during the period. Pictet Asset Management Holding SA’s holdings in Supernus Pharmaceuticals were worth $22,269,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Sit Investment Associates Inc. increased its holdings in shares of Supernus Pharmaceuticals by 0.4% during the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after purchasing an additional 250 shares during the period. Maryland State Retirement & Pension System boosted its stake in shares of Supernus Pharmaceuticals by 3.6% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after buying an additional 290 shares during the period. SummitTX Capital L.P. boosted its stake in shares of Supernus Pharmaceuticals by 2.7% in the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock valued at $580,000 after buying an additional 303 shares during the period. Royal Bank of Canada grew its position in Supernus Pharmaceuticals by 5.4% during the fourth quarter. Royal Bank of Canada now owns 6,987 shares of the specialty pharmaceutical company’s stock worth $346,000 after buying an additional 355 shares in the last quarter. Finally, Covestor Ltd increased its stake in Supernus Pharmaceuticals by 16.2% during the 4th quarter. Covestor Ltd now owns 2,683 shares of the specialty pharmaceutical company’s stock worth $133,000 after acquiring an additional 374 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently commented on SUPN shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $47.41 on Thursday. The stock has a market capitalization of $2.75 billion, a price-to-earnings ratio of -92.96, a PEG ratio of 0.99 and a beta of 0.54. The business’s fifty day moving average is $47.24 and its 200-day moving average is $49.51. Supernus Pharmaceuticals, Inc. has a one year low of $31.35 and a one year high of $59.68.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.